Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Neurology | Musculoskeletal | Family Medicine
Disease Category: Multiple Sclerosis
Location: United States, ND
MS - Central Neuropathic Pain due to Multiple Sclerosis
Study to compare discontinuation symptoms in abrupt discontinuation versus a 1-week tapering regimen in patients with Major Depressive Disorder treated for 24 weeks with open -label 50mg Desvenlafaxind Succinate Sustained-Release formulation.
Patient Inclusion Criteria:
- Male or female outpatient subjects aged 18 years or older, who are fluent in both written and spoken English, primary diagnosis of MDD, depressive symptoms for at least 30 days before the baseline visit.
- Reliable method of birth control for the duration of the study and for 15 days after the last dose of investigational product.
Patient Exclusion Criteria:
- Women who are pregnant, breastfeeding, or plan to become pregnant during the study. No medical conditions such as: hepatic disease, renal disease, pulmonary disease, cardiovascular (including uncontrolled hypertension and unstable angina), opthalmologic disease, neurological disorder/condition, or uncontrolled diabetes. Known or suspected allergy to venlafaxine, current diagnosis(within 12 months before screening) of an anxiety disorder considered to be primary, depression due to a general medical condition, including a neurological disorder.
Dr. Thomas Davis, Director
Legacy Pharma Research
601 N. 5th St.
Bismarck, ND 58501
Research Center Information: Legacy Pharma Research
If you would like to learn more about participating in this study, please send an email message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these